TSC2 and benign neoplasm: Disruption in the TSC1/TSC2 complex leads to constitutive activation of mTORC1, resulting in unchecked protein synthesis, cell cycle progression, and ultimately the development of benign tumors, or hamartomas, characteristic of TSC.